Results 141 to 150 of about 9,647,443 (317)

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

open access: yesMolecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker   +14 more
wiley   +1 more source

Obama Remains Unpopular in NH 5/29/15 [PDF]

open access: yes, 2015
President Barack Obama’s favorability and job approval ratings continue to remain at low levels in New Hampshire. Perceptions of the administration’s handling of the economy and foreign affairs also remain low, and Granite Staters think the country ...
Survey Center, UNH
core   +1 more source

LA-ICP-MS Zircon U-Pb Isotopic Dating: Constraints on the Time of the Daoxiang Formation in North Fujian Province

open access: yesYankuang ceshi, 2014
Although there is poor outcrop in the area, the Daoxiang formation exposed in North Fujian has unique rock assemblage and metamorphism, and deformation characteristics show that the Daoxiang group does exist, and belongs to metamorphic rock of the ...
ZHAO Xi-lin   +6 more
doaj  

Leaf adaptation strategy of non-tree plants altered by community structure implies vegetation degradation risk in alpine rocky desertification areas

open access: yesScientific Reports
In alpine rocky desertification areas, environmental stress poses challenges to vegetation restoration and protection. Merely observing the changes in specific leaf area driven by environmental factors may overlook the risk of non-tree vegetation ...
Jialiang Shi   +9 more
doaj   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

open access: yesMolecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen   +13 more
wiley   +1 more source

Obama Begins Presidency with High Marks in NH 2/16/2009 [PDF]

open access: yes, 2009
President Barack Obama has high approval ratings in New Hampshire during the early stages of his ...
Survey Center, UNH
core   +1 more source

Surveys

open access: yesAustralian Journal of Physiotherapy, 2005
Grimmer, Karen, Bialocerkowski, Andrea
openaire   +2 more sources

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha   +6 more
wiley   +1 more source

MA Special Senate Election Poll 1/10/2010 [PDF]

open access: yes, 2010
TITLE: MA Democratic Primary Election Poll 11/22 ...
Survey Center, UNH
core   +1 more source

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy